特应性皮炎
医学
干预(咨询)
信号转导
免疫学
过敏
药理学
过敏性接触性皮炎
过敏性
免疫球蛋白E
细胞因子
免疫病理学
通路分析
作者
Zheng Huang,Qing Zhang,Jianxin Zhao,Catherine Stanton,R. Paul Ross,Wei Chen,Bo Kyung Yang
标识
DOI:10.1021/acs.jafc.6c02316
摘要
Atopic dermatitis (AD) is a prevalent early childhood inflammatory skin disease frequently linked to gut dysbiosis. While Bifidobacterium longum subsp. infantis is a pioneer infant gut colonizer driving immune maturation, its role in AD prevention remains unclear. Here, we investigated early life intervention with B. longum subsp. infantis CCFM1269 using a 2,4-dinitrofluorobenzene (DNFB)-induced murine AD model. Oral administration of CCFM1269 significantly ameliorated AD symptoms, reducing skin/ear thickness, dermatitis scores, and serum IgE. Mechanistically, CCFM1269 modulated the systemic Th1/Th2 balance by downregulating TSLP, IL-4, and IL-13, while upregulating IFN-γ. Notably, CCFM1269 produced indole-3-lactic acid (ILA). Via the gut-skin axis, ILA activated the aryl hydrocarbon receptor (AHR) and its target CYP1A1 in skin tissues, strengthening the epidermal barrier. Additionally, AD mitigation was associated with gut microbiota reshaping. Ultimately, CCFM1269 alleviates AD primarily through the ILA- AHR signaling pathway, highlighting its potential as a functional food ingredient for early life AD prevention.
科研通智能强力驱动
Strongly Powered by AbleSci AI